氯吡格雷联合降纤治疗对脑梗死复发影响的临床观察  

Clinical observation of clopidogrel combined with lumbrukinase on prevention of celebral infarct recurrence

作　　者：任于果[1] 宫鹏[2] 李维祖[3] 

机构地区：[1]安徽医科大学第一附属医院神经内科,合肥230022 [2]安徽医科大学第一附属医院药剂科,合肥230022 [3]安徽医科大学药理教研室

出　　处：《安徽医学》2010年第10期1227-1229,共3页Anhui Medical Journal

摘　　要：目的研究氯吡格雷和蚓激酶长期联合治疗对脑梗死复发的影响及其安全性。方法对2007年1月至2008年12月住院的167例脑梗死患者在出院后随机分为氯吡格雷和蚓激酶联合治疗组,氯吡格雷对照组。治疗组给予氯吡格雷50mg每天1次+蚓激酶2粒每天3次,对照组给予氯吡格雷50mg每天1次,观察2年内两组患者的脑梗死复发情况和不良反应。结果氯吡格雷和蚓激酶联合治疗组脑梗死复发率(5.88%)明显低于对照组发病率(10.97%),治疗组和对照组出血不良反应差异无统计学意义。结论氯吡格雷和蚓激酶长期联合治疗对预防脑梗死复发临床疗效确切明显,且不增加出血风险。Objective To observe the clinical effect of clopidogrel combined with lumbrukinase on provention of celebral infarct recurrence for a long time.Methods From January 2007 to December 2008,167 cases of acute cerebral infarction from the Department of Neurology,the NO.1 affliated hospital of Anhui medical university were selected and divided into two groups randomly.Besides the routine basic treatment,Two lumbrukinase capsules（three times a day,taken 30 minutes before meals）and clopidogre l（50mg once a day）were given to all 85 cases in the experimental group.While only clopidogrel tablets（50mg once a day）were given to the 82 cases in control group.All the subjects were treated for a coures of two years for observing the recurrence and side-effect.Results The recurence rate of the experimental group was less than that of the control group（5.88%,10.97%,P0.05）.there are no significant statistical difference in hemorrhagic side-effect of the two groups.Conclusion The long term treatment of clopidogrel associated with lumbrukinase on provention of ischemic stroke recurrence is superior to single medicinal treatment.which can remarkably cut down the recurrence rate and is safety.

关 键 词：氯吡格雷 蚓激酶 脑梗死 纤维蛋白原 

分 类 号：R743.3[医药卫生—神经病学与精神病学]